ClinicalTrials.gg
CompletedNCT00163189Updated Feb 21, 2024Results posted

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

A Phase 3 interventional study of Somatropin in Growth Hormone Deficiency, sponsored by Pfizer. Completed at 19 sites in France. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
23rd of 60
98 · median 66
Started
2005
with 4 others
Phase 3
23 of 60
2 open now
Registered
7th of 60
by date
Lead sponsor
5 of 60
Pfizer

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 23rd largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 7th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glucocorticosteroid treatment for 12 months at least
  • Bone age \< 15 years for a boy and \< 13 years for a girl
  • Child measured height \< - 2 SD, Child currently treated by GH

Exclusion criteria

Exclusion Criteria:

  • Known diabetes (type 1 or type 2)
  • A previous history of intolerance or to the study drug or to drugs with similar chemical structures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: Somatropin

Interventions

  • Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

    Time frame: Baseline, Month 36

  2. Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

    Time frame: Baseline, Month 36

Secondary outcomes

  1. Mean Height

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  2. Mean Height Standard Deviation Score (SDS) for Bone Age (BA)

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  3. Annual Growth Rate (AGR)

    AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and re scaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). Yx refers to the value at particular timepoint x.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  4. Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)

    GR SDS BA Yx = (GR Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. BA was estimated locally using an X-ray from the left wrist and hand.

    Time frame: Month 12, 24, 36, 48, 60

  5. Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)

    GR SDS CA Yx = (GR Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  6. Body Mass Index (BMI)

    BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2).

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  7. Change From Baseline in Height at Month 12, 24, 36, 48 and 60

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  8. Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

    Time frame: Baseline, Month 12, 24, 48, 60

  9. Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60

    The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  10. Change From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60

    BA was estimated locally using an X-ray from the left wrist and hand.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

  11. Ratio of Bone Age (BA) to Chronological Age (CA)

    BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.

    Time frame: Baseline, Month 12, 24, 36, 48, 60

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs include both SAEs and non-SAEs.

    Time frame: Baseline up to 28 days after last study treatment

  2. Number of Participants With Significant Changes in Physical Examinations

    Number of participants with clinically significant physical examinations changes since previous visit were reported. Physical examination including estimation of pubertal stage and blood pressure measurement;

    Time frame: Baseline, Month 12, 24, 36, 48, 60, End of Treatment (EOT)

  3. Number of Participants With at Least 1 Medical or Surgical History

    Time frame: Screening

  4. Number of Participants Who Received Concomitant Medications

    Time frame: Baseline up to Month 60

  5. Fasting Serum Insulin Like Growth Factor-1 (IGF-1) Levels

    Time frame: Screening, Month 6, 12, 18, 24, 30, 36, 42, 48, 54, 60

  6. Fasting and Postprandial Plasma Glucose Levels at Month 12, 24, 36, 48 and 60

    Fasting and 2 hours plasma glucose levels were assessed using standard oral glucose tolerance test (OGTT).

    Time frame: Screening, Month 12, 24, 36, 48, 60

07

Results

Posted Jun 25, 2015

Participant flow

Participant flow — Overall Study
MilestoneGenotonorm
Started98
Completed35
Not completed63
Withdrew: Other6
Withdrew: Lost to follow-up1
Withdrew: Protocol violation2
Withdrew: Death3
Withdrew: Adverse event6
Withdrew: Lack of efficacy7
Withdrew: Study terminated by sponsor11
Withdrew: Withdrawal by subject11
Withdrew: Did not meet continuation criterion16

Outcome measures

PrimaryChange From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Time frame:
Baseline, Month 36
Reported as:
Mean · Standard Deviation Score (SDS)
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population
Standard Deviation Score (SDS)Genotonorm
Baseline (n=58)-2.91 ± 1.19
Change at Month 36 (n=30)0.80 ± 1.03
Statistical analysis
  • Genotonorm · Student's paired t-test · p = <0.001
PrimaryChange From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Time frame:
Baseline, Month 36
Reported as:
Mean · SDS
Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population
SDSGenotonorm
Baseline (n=21)-2.86 ± 0.89
Change at Month 36 (n=19)0.81 ± 1.18
Statistical analysis
  • Genotonorm · Student's paired t-test · p = 0.008
SecondaryMean Height

The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · centimeters (cm)
Mean Height
centimeters (cm)Genotonorm
Baseline (n=58)133.9 ± 15.7
Month 12 (n=50)139.5 ± 16.8
Month 24 (n=41)146.0 ± 16.4
Month 36 (n=30)150.4 ± 16.0
Month 48 (n=14)152.4 ± 16.0
Month 60 (n=9)156.0 ± 11.3
SecondaryMean Height Standard Deviation Score (SDS) for Bone Age (BA)

The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · SDS
Mean Height Standard Deviation Score (SDS) for Bone Age (BA)
SDSGenotonorm
Baseline (n=51)-0.29 ± 1.15
Month 12 (n=40)-0.36 ± 1.52
Month 24 (n=29)0.11 ± 1.36
Month 36 (n=24)0.14 ± 1.48
Month 48 (n=13)-0.26 ± 1.28
Month 60 (n=7)-0.19 ± 1.15
SecondaryAnnual Growth Rate (AGR)

AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and re scaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). Yx refers to the value at particular timepoint x.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · cm/year
Annual Growth Rate (AGR)
cm/yearGenotonorm
Baseline (n=52)3.0 ± 2.0
Month 12 (n=49)6.7 ± 2.6
Month 24 (n=41)6.0 ± 2.7
Month 36 (n=30)5.9 ± 2.7
Month 48 (n=14)4.8 ± 2.5
Month 60 (n=9)4.9 ± 3.0
SecondaryGrowth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)

GR SDS BA Yx = (GR Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. BA was estimated locally using an X-ray from the left wrist and hand.

Time frame:
Month 12, 24, 36, 48, 60
Reported as:
Mean · SDS
Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)
SDSGenotonorm
Month 12 (n=36)-0.13 ± 2.15
Month 24 (n=25)0.07 ± 2.51
Month 36 (n=20)0.05 ± 1.94
Month 48 (n=11)-1.00 ± 1.38
Month 60 (n=7)-0.43 ± 1.22
SecondaryGrowth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)

GR SDS CA Yx = (GR Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · SDS
Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)
SDSGenotonorm
Baseline (n=52)-2.04 ± 2.03
Month 12 (n=49)1.77 ± 4.29
Month 24 (n=41)5.26 ± 16.79
Month 36 (n=29)3.64 ± 9.06
Month 48 (n=13)0.93 ± 2.73
Month 60 (n=9)1.40 ± 1.71
SecondaryBody Mass Index (BMI)

BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2).

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · kg/m^2
Body Mass Index (BMI)
kg/m^2Genotonorm
Baseline (n=58)19.4 ± 3.6
Month 12 (n=50)19.1 ± 3.1
Month 24 (n=41)19.4 ± 3.0
Month 36 (n=30)19.4 ± 2.4
Month 48 (n=14)19.7 ± 3.0
Month 60 (n=9)20.8 ± 3.3
SecondaryChange From Baseline in Height at Month 12, 24, 36, 48 and 60

The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · cm
Change From Baseline in Height at Month 12, 24, 36, 48 and 60
cmGenotonorm
Baseline (n=58)133.9 ± 15.7
Change at Month 12 (n=50)6.8 ± 2.8
Change at Month 24 (n=41)12.9 ± 4.7
Change at Month 36 (n=30)18.8 ± 6.1
Change at Month 48 (n=14)23.9 ± 8.5
Change at Month 60 (n=9)30.3 ± 7.6
SecondaryChange From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60

The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.

Time frame:
Baseline, Month 12, 24, 48, 60
Reported as:
Mean · SDS
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60
SDSGenotonorm
Baseline (n=58)-2.91 ± 1.19
Change at Month 12 (n=50)0.28 ± 0.57
Change at Month 24 (n=41)0.57 ± 0.95
Change at Month 48 (n=14)0.82 ± 1.42
Change at Month 60 (n=9)0.75 ± 1.13
SecondaryChange From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60

The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · SDS
Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60
SDSGenotonorm
Baseline (n=51)-0.29 ± 1.15
Change at Month 12 (n=36)-0.02 ± 0.99
Change at Month 24 (n=26)0.28 ± 1.18
Change at Month 36 (n=21)0.31 ± 1.17
Change at Month 48 (n=13)-0.08 ± 1.30
Change at Month 60 (n=7)0.01 ± 1.33
SecondaryChange From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60

BA was estimated locally using an X-ray from the left wrist and hand.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · months
Change From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60
monthsGenotonorm
Baseline (n=58)117.9 ± 34.6
Change at Month 12 (n=37)17.8 ± 11.0
Change at Month 24 (n=32)28.2 ± 17.9
Change at Month 36 (n=23)36.5 ± 17.8
Change at Month 48 (n=13)52.8 ± 21.2
Change at Month 60 (n=7)70.0 ± 27.0
SecondaryRatio of Bone Age (BA) to Chronological Age (CA)

BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.

Time frame:
Baseline, Month 12, 24, 36, 48, 60
Reported as:
Mean · ratio
Ratio of Bone Age (BA) to Chronological Age (CA)
ratioGenotonorm
Baseline (n=58)0.78 ± 0.10
Month 12 (n=37)0.82 ± 0.11
Month 24 (n=32)0.80 ± 0.09
Month 36 (n=23)0.79 ± 0.10
Month 48 (n=13)0.81 ± 0.08
Month 60 (n=7)0.85 ± 0.10
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs include both SAEs and non-SAEs.

Time frame:
Baseline up to 28 days after last study treatment
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsGenotonorm
AEs84
SAEs45
Other pre-specifiedNumber of Participants With Significant Changes in Physical Examinations

Number of participants with clinically significant physical examinations changes since previous visit were reported. Physical examination including estimation of pubertal stage and blood pressure measurement;

Time frame:
Baseline, Month 12, 24, 36, 48, 60, End of Treatment (EOT)
Reported as:
Number · participants
Number of Participants With Significant Changes in Physical Examinations
participantsGenotonorm
Baseline (n=93)1
Month 12 (n=93)16
Month 24 (n=72)16
Month 36 (n=52)5
Month 48 (n=23)4
Month 60 (n=12)2
EOT (n=44)11
Other pre-specifiedNumber of Participants With at Least 1 Medical or Surgical History
Time frame:
Screening
Reported as:
Number · participants
Number of Participants With at Least 1 Medical or Surgical History
participantsGenotonorm
Number of Participants With at Least 1 Medical or Surgical History67
Other pre-specifiedNumber of Participants Who Received Concomitant Medications
Time frame:
Baseline up to Month 60
Reported as:
Number · participants
Number of Participants Who Received Concomitant Medications
participantsGenotonorm
Number of Participants Who Received Concomitant Medications98
Other pre-specifiedFasting Serum Insulin Like Growth Factor-1 (IGF-1) Levels
Time frame:
Screening, Month 6, 12, 18, 24, 30, 36, 42, 48, 54, 60
Reported as:
Mean · nanogram per milliliter (ng/mL)
Fasting Serum Insulin Like Growth Factor-1 (IGF-1) Levels
nanogram per milliliter (ng/mL)Genotonorm
Screening (n=93)335 ± 157
Month 6 (n=63)604 ± 291
Month 12 (n=71)538 ± 268
Month 18 (n=47)624 ± 251
Month 24 (n=62)579 ± 262
Month 30 (n=50)559 ± 250
Month 36 (n=44)511 ± 186
Month 42 (n=22)555 ± 224
Month 48 (n=21)581 ± 244
Month 54 (n=16)593 ± 184
Month 60 (n=10)501 ± 180
Other pre-specifiedFasting and Postprandial Plasma Glucose Levels at Month 12, 24, 36, 48 and 60

Fasting and 2 hours plasma glucose levels were assessed using standard oral glucose tolerance test (OGTT).

Time frame:
Screening, Month 12, 24, 36, 48, 60
Reported as:
Mean · milli mole per liter (mmol/L)
Fasting and Postprandial Plasma Glucose Levels at Month 12, 24, 36, 48 and 60
milli mole per liter (mmol/L)Genotonorm
Glucose Fasting: Screening (n=91)4.5 ± 0.7
Glucose Fasting: Month 12 (n=69)4.6 ± 0.7
Glucose Fasting: Month 24 (n=59)4.7 ± 0.6
Glucose Fasting: Month 36 (n=45)4.6 ± 0.5
Glucose Fasting: Month 48 (n=20)4.7 ± 0.4
Glucose Fasting: Month 60 (n=14)4.5 ± 0.6
Glucose Postprandial: Screening (n=94)5.6 ± 1.2
Glucose Postprandial: Month 12 (n=66)6.1 ± 1.4
Glucose Postprandial: Month 24 (n=59)6.1 ± 1.4
Glucose Postprandial: Month 36 (n=41)6.4 ± 1.6
Glucose Postprandial: Month 48 (n=19)6.1 ± 1.1
Glucose Postprandial: Month 60 (n=13)6.3 ± 1.5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotonorm—45/98 (45.9%)81/98 (82.7%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventGenotonorm
GastroenteritisInfections and infestations8/98
Nephrotic syndromeRenal and urinary disorders7/98
Renal failureRenal and urinary disorders5/98
SepsisInfections and infestations3/98
DeathGeneral disorders3/98
DehydrationMetabolism and nutrition disorders3/98
Urinary tract infectionInfections and infestations2/98
VaricellaInfections and infestations2/98
ProteinuriaRenal and urinary disorders2/98
DiarrhoeaGastrointestinal disorders2/98
Most frequent other events
Showing 10 of 180
Most frequent other events
EventGenotonorm
Insulin-like growth factor increasedInvestigations13/98
Nephrotic syndromeRenal and urinary disorders11/98
DiarrhoeaGastrointestinal disorders9/98
ArthralgiaMusculoskeletal and connective tissue disorders9/98
BronchitisInfections and infestations8/98
AstheniaGeneral disorders8/98
Glucose tolerance impairedMetabolism and nutrition disorders8/98
HeadacheNervous system disorders8/98
PyrexiaGeneral disorders7/98
NasopharyngitisInfections and infestations6/98

Baseline characteristics

Safety analysis set included all participants (including a site with GCP issues) who had received at least 1 study dose of growth hormone (GH).

Age, Continuous
Age, Continuous(years)Genotonorm
Mean11.8 ± 3.2
Sex: Female, Male
Sex: Female, Male(Participants)Genotonorm
Female24
Male74
08

Study locations

19 sites
  • Hôpital Nord
    Amiens, 80030, France
  • Centre Hospitalier Intercommunal d'Annemasse-Bonneville, Service de Pédiatrie et Néonatologie
    Annemasse Cedex, 74107, France
  • Hôpital Saint Jacques
    Besancon Cedex, 25030, France
  • Groupe hospitalier Est- Hôpital Femme, Mère, Enfant
    Bron, 69677, France
  • Groupe hospitalier Est-Hôpital Femme, Mère, Enfant
    Bron, 69677, France
  • CHU d'Estaing
    Clermont-Ferrand Cedex 1, 63003, France
  • CHU de Grenoble, Hôpital Couple enfant.
    Grenoble Cedex 9, 38043, France
  • CHU Timone Enfants
    Marseille Cedex 5, 13385, France
  • Hôpital Arnaud De Villeneuve
    Montpellier, 34059, France
  • CHU de Nantes, Hôpital Mère Enfant
    Nantes cedex 1, 44093, France
  • Hôpital Lenval
    Nice, 06200, France
  • Groupe Hospitalier Necker - Enfants Malades
    Paris cedex 15, 75743, France
  • Hôpital Robert Debré
    Paris, 75019, France
  • Hôpital Armand Trousseau
    Paris, 75571, France
  • Centre de Perharidy
    Roscoff Cedex, 29684, France
  • CHU Charles Nicolle
    Rouen Cedex, 76031, France
  • Service de Pédiatrie- Centre Hospitalier Intercommunal
    Saint Germain-en-Laye Cedex, 78105, France
  • Hôpital des Enfants
    Toulouse Cedex 9, 31059, France
  • CHU Tours - Centre Pediatrique Gatien de Cocheville
    Tours Cedex 1, 37044, France
09

References and documents

Publications

  • Basmaison O, Ranchin B, Zouater H, Robertson A, Gomez R, Koppiker N. Efficacy and safety of recombinant growth hormone treatment in children with growth retardation related to long-term glucocorticosteroid therapy. Ann Endocrinol (Paris). 2019 Sep;80(4):202-210. doi: 10.1016/j.ando.2019.02.001. Epub 2019 Mar 4. PubMed 30910221 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Jan 2005
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jun 25, 2015
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00163189
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Jan 2005
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jun 25, 2015
Last update
Feb 21, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion